IL2 and metastatic melanoma: HD-IL-2 suppresses CD4 + CD25hi-FoxP3+ T-regulatory cells, the prime contact-dependent suppressors of antigen-specific T cell response in metastatic melanoma patients, with a demonstrable clinical benefit.